Kogenate FS

antihemophilic factor (recombinant) for the treatment of Hemophilia A

Free Trial| EZ Log| Prescribing Information

Contact Us

Search

Advancing the Science

Driving science to improve real care for today and develop next-generation products for tomorrow

At Bayer HealthCare, we believe that real life demands commitment for today and tomorrow. We are passionate about improving the lives of people living with hemophilia A.

Bayer HealthCare has been dedicated to improving the lives of people living with hemophilia A by expanding scientific and clinical knowledge that improves patient care. Over the past two decades, Bayer has:

  • Supported local and international hemophilia patient groups such as the National Hemophilia Foundation (NHF) in their advocacy and patient care initiatives.
  • Supported innovative educational and training programs to improve the diagnosis and care of people with bleeding disorders around the world.
  • Donated more than 30 million international units of product to countries with limited access to hemophilia treatment, bringing hope and saving lives.

We remain committed, as we have for decades, to helping improve and enhance the lives of patients and families who live with bleeding disorders and to continuing to inform the healthcare professionals who treat these patients.

We currently have a long-acting recombinant factor VIII protein in human clinical trials. We are also creating new and innovative delivery systems that decrease the discomfort of infusion and increase convenience.

Bayer HealthCare sponsors ongoing clinical studies investigating treatment benefits and long-acting rFVIII replacement options

  • Bayer HealthCare continues to provide grants through the Bayer Hemophilia Awards Program that support basic and clinical research in hemophilia 138 grants totaling more than $15 million have been awarded since the program’s inception in 2002
    • Projects funded through the program have led to more than 100 publications and abstracts
  • Bayer HealthCare invests aggressively and consistently in Research and Development
  • Bayer HealthCare continues to seek out opportunities to license products and technologies

If you have a specific technical or clinical question concerning Kogenate® FS, please contact your Hematology Account Executive or contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937).

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of hightiter inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2010 Bayer HealthCare Pharmaceuticals, Inc. All rights reserved.
BAYER, the Bayer Cross, and Kogenate FS are registered trademarks of Bayer HealthCare Pharmaceuticals.
BIO-SET is a trademark of Biodome SAS.

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System

Bayer HealthCare Pharmaceuticals